Research map: Concordance of folate receptor expression in ovarian cancer over time: A single-institution retrospective study

Back to the article

Papers in this map

  1. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer · Kathleen N. Moore · 2023 · 481 citations · Cited by this paper
  2. Ecthyma gangrenosum in a patient with metastatic leiomyosarcoma undergoing chemotherapy: a case report · 2026 · Related
  3. Folate receptor alpha as a tumor target in epithelial ovarian cancer · Kimberly R. Kalli · 2008 · 478 citations · Cited by this paper
  4. Face-to-face or screen-to-screen: gynecologic oncology fellowship interview applicant perspectives on interview format · 2026 · Related
  5. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study · Ursula A. Matulonis · 2023 · 395 citations · Cited by this paper
  6. KAT6B/A::KANSL1 uterine sarcoma – A case with recurrences following uterine morcellation and the development of primary cell line model · 2026 · Related
  7. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I · Kathleen N. Moore · 2021 · 304 citations · Cited by this paper
  8. Lights genes action: Video strategy for BRCA1/2 patient education · 2026 · Related
  9. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study · Kathleen N. Moore · 2017 · 225 citations · Cited by this paper
  10. Impact of patient neighborhood area deprivation index on prognostic factors and outcomes in endometrioid adenocarcinoma of the endometrium: a retrospective multi-center healthcare network analysis · 2026 · Related
  11. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer · Asma Ali Dilawari · 2023 · 118 citations · Cited by this paper
  12. Recent treatment outcomes of cervical intraepithelial neoplasia in south western Uganda: a six year retrospective study · 2026 · Related
  13. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes · Heather J. Bax · 2022 · 92 citations · Cited by this paper
  14. Master Class: Writing a Case Report – Reflections on a Recently Published Case Report · 2026 · Related
  15. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer · Lucia M. A. Crane · 2011 · 88 citations · Cited by this paper
  16. Low-grade serous carcinoma metastasizing to the chest wall and incidental Müllerian inclusion in a retrosternal lymph node 16 years after the initial ovarian serous borderline tumor: a case report · 2026 · Related
  17. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy · Evelyn Despierre · 2013 · 76 citations · Cited by this paper
  18. Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical study · 2026 · Related
  19. “Recurrence within 6 Months of Platinum Therapy”: An Adequate Definition of “Platinum-Refractory” Ovarian Cancer? · Maurie M. Markman · 1998 · 42 citations · Cited by this paper
  20. Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination · Valentina Angerilli · 2025 · 17 citations · Cited by this paper
  21. Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma · Brooke Liang · 2025 · 7 citations · Cited by this paper
  22. Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort. · Elizabeth M. Swisher · 2025 · 4 citations · Cited by this paper
  23. Real-world analysis of folate receptor alpha (FRα; FOLR1) expression in pan-tumor samples from over 6000 patients in the US. · Thomas C. Krivak · 2025 · 3 citations · Cited by this paper
  24. The impact of clinical sample collection timing on FRα expression and mirvetuximab soravtansine patient outcomes in the MIRASOL (GOG 3045/ENGOT-ov55) trial · Sabrina Chiara Cecere · 2026 · 1 citation · Cited by this paper
  25. Untitled · Cited by this paper

Source: OpenAlex (CC0)